RXi Pharmaceuticals (RXII)
Create an AlertRXII Key Stats
| Income Statement | |
| Revenue TTM | 0.15M |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -0.2566 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -25.35M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -27164% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 67.29M |
| Enterprise Value | 47.65M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 8.289 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | |
| Return on Equity | |
RXII News
- RXi Pharmaceuticals (RXII) Shares to Begin Trading on OTCQX® Accesswire Jun 19
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Of... Jun 13
- RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study i... Jun 6
- RXi Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conferenc... May 20
- RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2013 Marketwired May 15
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial... May 15
- RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report May 15
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results GlobeNewswire May 9
- RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and P... May 9
- GALENA BIOPHARMA, INC. Financials Nov 17
RXII Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). RXi Pharmaceuticals is up 172.2% over the last year vs S&P 500 Total Return up 23.89%, ARCA biopharma down 57.69%, and Advanced Proteome Therpt up 146.7%.
RXII Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these RXII related companies
Pro Ratings for RXII
Pro Strategies Featuring RXII
Did RXi Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
RXII Profile
Sector: Healthcare
Industry: Biotechnology
Other RXII Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RXII | 0.199 | +0.00 | +0.00% | 67.29M |
